Evidence map›Paper›PMID 25904246›Full record

ArticleBlood2015

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Nancy Y Villa, Clive H Wasserfall, Amy M Meacham, Elizabeth Wise, Winnie Chan, John R Wingard, Grant McFadden, Christopher R Cogle

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.International journal of molecular sciences · 2021
    Review
  13. Article
  14. Article
  15. Oncolytic Viruses and the Immune System: The Dynamic Duo.Molecular therapy. Methods & clinical development · 2020
    Review
  16. Review
  17. Oncolytic Virotherapy with Myxoma Virus.Journal of clinical medicine · 2020
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nancy Y VillaDivision of Hematology and Oncology, Department of Medicine.
Clive H WasserfallDepartment of Pathology, Immunology and Laboratory Medicine, and.
Amy M MeachamDivision of Hematology and Oncology, Department of Medicine.
Elizabeth WiseDivision of Hematology and Oncology, Department of Medicine.
Winnie ChanDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL.
John R WingardDivision of Hematology and Oncology, Department of Medicine.
Grant McFaddenDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL.
Christopher R CogleDivision of Hematology and Oncology, Department of Medicine.
University of Florida · US

Funding

Manipulation of inflammasomes and NF-kB signaling in human myeloid cells by MyxomR01AI100987 · NIAID · UNIVERSITY OF FLORIDA · PI MCFADDEN, GRANT · 2013 to 2017
$1.9M
Myxoma Virus (MV) Oncolysis for treating human cancerR01CA138541 · NCI · UNIVERSITY OF FLORIDA · PI MCFADDEN, GRANT · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA138541NCI NIH HHS R01 CA138541-01NIAID NIH HHS R01 AI100987
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-host disease (GVHD) is a major limitation for wider application. Ideally, strategies to improve allo-HCT would involve suppression of T lymphocytes that drive GVHD while sparing those that mediate graft-versus-malignancy (GVM). Recently, using a xenograft model, we serendipitously discovered that myxoma virus (MYXV) prevented GVHD while permitting GVM. In this study, we show that MYXV binds to resting, primary human T lymphocytes but will only proceed into active virus infection after the T cells receive activation signals. MYXV-infected T lymphocytes exhibited impaired proliferation after activation with reduced expression of interferon-γ, interleukin-2 (IL-2), and soluble IL-2Rα, but did not affect expression of IL-4 and IL-10. MYXV suppressed T-cell proliferation in 2 patterns (full vs partial) depending on the donor. In terms of GVM, we show that MYXV-infected activated human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells. Given this dual capacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy with MYXV may be a promising clinical adjunct to allo-HCT regimens.

Indexed as

Cell Line, TumorCell ProliferationCells, CulturedGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLymphocyte ActivationMultiple MyelomaMyxoma virusOncolytic VirotherapyOncolytic VirusesPoxviridae InfectionsT-LymphocytesTumor Virus Infections

Identifiers

PMID25904246
PMCPMC4463738
OpenAlexW2085947800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.